Is pre-assessment for anti-TNF therapy in RA necessary in the UK? Analysis of DAS28 in six centres

Rheumatology

Volumn 46, Issue 10, 2007, Pages 1557-1559

  Smith, N ^a   Gadsby, K ^a   Butt, S ^b   Carruthers, D ^b   Deeming, A ^b   Ledingham, J ^c   Fletcher, M ^c   Mulherin, D ^d   Roskell, S ^d   Kay, L ^e   Nicholl, K ^e   Cooper, R ^f   Worsley, A ^f   Deighton, Chris ^a  

^a DERBYSHIRE ROYAL INFIRMARY   (United Kingdom)

^b SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST   (United Kingdom)

^c QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^d ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^e FREEMAN HOSPITAL   (United Kingdom)

^f HOPE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ANTIBODY;

ARTHRALGIA; ARTICLE; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; STUDENT T TEST; UNITED KINGDOM; VISUAL ANALOG SCALE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34848928468     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem188     Document Type: Article

References (19)

1. British Society for Rheumatology. Guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. London: British Society for Rheumatology, 2001? (www.rheumatology.org.uk).
2. Van Gestel A, Prevoo M, van't Hof M et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-44.
3. National Institute for Health and Clinical Excellence. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. Health Technology Guidance. No.36 London, National Institute for Health and Clinical Excellence, 2002.
4. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNF-α blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005;44:157-63.
5. NICE Technology Appraisal - Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (final appraisal determination) www.nice.org.uk.
6. British Society for Rheumatology.Guidelines for prescribing TNFα blockers in adults with ankylosing spondylitis. London: British Society for Rheumatology, 2004, (www.rheumatology.org.uk).
7. National Institute for Health and Clinical Excellence. Etanercept and infliximab for the treatment of adults with psoriatic arthritis. Technology Appraisal No.104 (www.nice.org.uk/TA104).
8. Kyle S, Chandler D, Griffiths C et al on behalf of the British Society for Rheumatology Standards Guidelines Audit Working Group (SGAWG). Guideline for anti-TNF-α therapy in psoriatic arthritis. Rheumatology 2005;44:390-7.
9. Srikanth A, Gadsby K, Roskell S, Mulherin D, Deighton C. Is preassessment necessary for rheumatoid arthritis anti-TNF therapy? Rheumatology 2006;45:i48.
10. Wolfe F, Michaud K, Pincus T et al. The Disease Activity Score is not suitable as the sole criterion for initiation and evaluation of anti-tumour necrosis factor therapy in the clinic: Discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum 2005;52:3873-9.
11. Harth M, Pope J. The measure of our measures. Rheumatology 2004;43:1465-7.
12. Leeb BF, Andel I, Sautner J, Nothnagl T, Rintelen B. The DAS28 in rheumatoid arthritis and fibromyalgia patients. Rheumatology 2004;43:1504-7.
13. Estrach C, Mpofu S, Thompson R, Williams E, Abernethy V, Moots R. Swollen joint count as a predictor of response to anti-tumour necrosis factor α therapy in rheumatoid arthritis: Comment on the article by Sokka and Pincus. Arthritis Rheum 2003;48:3611-3.
14. Furst D, Breedveld F, Kalden J et al. Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases. Ann Rheum Dis 2005;64:iV2-iv14.
15. Irish Society for Rheumatology. Guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis. www.isr.ie.
16. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis 2002 update. Arthritis Rheum 2002;46:328-46.
17. Hjardem E, Hetland M, Østergaard M, Krogh N, Kvein T. Prescription practice of biological drugs in rheumatoid arthritis during the first 3 years of post-marketing use in Denmark and Norway: Criteria are becoming less stringent. Ann Rheum Dis 2005;64:1220-3.
18. Valesini G, Montecucco C, Cutulo M. Recommendations for the use of biologic (TNF-α blocking) agents in the treatment of rheumatoid arthritis in Italy. Clin Exp Rheumatol 2006;24:413-23.
19. Deighton CM, George E, Kiely P, Ledingham J, Luqmaani R, Scott DL. Updating the BSR guidelines for anti-TNF therapy in adult RA (again). Rheumatology 2006;45:649-52.